|
|
|
|
|
 |
Neutralizing Antibodies to Interferon Beta in the Treatment of Multiple Sclerosis
Program Overview
Target Audience
Educational Objectives
Disclaimer
CME Information
Credit Designation
Date of Release and Expiration
Statement of Responsibility
Privacy Statement Copyright 2004, The Johns Hopkins University School of Medicine. All rights reserved.
Faculty Dr. Calabresi is an associate professor of neurology and director of The Johns Hopkins Multiple Sclerosis (MS) Center. He specializes in the diagnosis and management of MS. As director of the MS clinic, Dr. Calabresi is the principal investigator on several clinical trials and also oversees translational laboratory research projects. Dr. Calabresi has designed and directed several clinical trials investigating combination drug therapies in MS. He is on the advisory board for 3 national multicenter clinical trials. Dr. Calabresi's specific laboratory research interest lies in understanding the mechanisms of T lymphocyte migration into the brain and spinal cord. He has published numerous articles on the adhesion molecules and chemokine receptors responsible for T cell homing to the brain in MS. He recently reported on a novel potassium channel, Kv1.3, which is specifically and highly expressed on chronically activated immune cells in the blood and brains of people with MS. The availability of Kv1.3 blocking drugs makes this an attractive future therapeutic target in MS. Dr. Calabresi was also recently awarded a 5-year collaborative MS center grant from the National Multiple Sclerosis Society to study mechanisms of neurodegeneration and strategies for neuroprotection in MS.
Steven L. Galetta, MD Dr. Galetta is currently the Van Meter Professor of Neurology and a member of the multiple sclerosis division at the University of Pennsylvania School of Medicine. He is also the director of the neuro-opthamology division and the neurology-training program. After earning his bachelor's degree from the University of Pennsylvania and his medical degree from the Cornell University Medical College, Dr. Galetta returned to Philadelphia where he completed his residency in neurology at the Hospital of the University of Pennsylvania. He then went on to complete a fellowship in neuro-ophthalmology at the Bascom Palmer Eye Institute in Miami, Florida. Dr. Galetta is board certified in neurology and neuro-ophthalmology. Dr. Galetta is published in several top medical journals and has been named one of the "Best Doctors in America" on numerous occasions. He is a member of the American Neurologic Association, the American Academy of Neurology, the Stroke Council, the Frank B. Walsh Society and the North American Neuro-Ophthalmology Society.
Robert Fox, MD Dr. Fox received his undergraduate degree from Amherst College and his medical degree from The Johns Hopkins University School of Medicine. He pursued residency training in neurology at the Hospital of the University of Pennsylvania in Philadelphia. He completed clinical training as a Potiker Fellow at the Mellen Center for Multiple Sclerosis Treatment and Research at The Cleveland Clinic Foundation, where he now continues as a staff neurologist. He is also the director of the Mellen Center MS tissue donation program.
Dusan Stefoski, MD Dr. Stefoski, a board-certified neurologist since 1980, is an associate professor of neurology at the Rush University Medical College, a senior attending neurologist at the Rush-Presbyterian-St. Luke's Medical Center and the director of the Rush Multiple Sclerosis Center in Chicago. Dr. Stefoski received his medical degree and concluded an internship at the University of Zagreb Medical School in Croatia (formerly Yugoslavia). He completed his neurology residency at Rush and his training in neuropathology at Stanford University. Dr. Stefoski, a fellow of the American Academy of Neurology, has been doing novel research in the field of MS at Rush and has been participating in collaborative projects with researchers in the United States and internationally.
In association with Dr. Floyd Davis, he pioneered the proof-of-concept and efficacy of
Faculty Disclosures Dr. Steven Galetta has been paid as a consultant to Biogen Idec and has received grant and research support, as well as honoraria from Biogen Idec. Dr. Peter Calabresi has received grant and research support and served as a consultant with Biogen Idec, Berlex, Inc., Teva Neuroscience, Inc. and Serono, Inc. Dr. Robert Fox has received grant and research from Biogen Idec and consulting fees and honoraria from Biogen Idec, Acorda Therapeutics, Serono, Inc. and Teva Neuroscience, Inc. Dr. Dusan Stefoski has received grant and research support as well as consulting fees from Biogen Idec, and has received honoraria from Biogen Idec, Berlex, Inc., Serono Inc., and Teva Pharmaceuticals.
Off-Label Discussion
This educational program is supported through an educational grant from Biogen Idec.
|
|
||||||||||||||||||||||||||||||||||||
